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Purpose: To determine whether chemoembolization using drug-eluting beads (DEB-TACE)
is safe and effective for liver transplantation candidates with liver-limited hepatocellular
carcinoma (HCC) without vascular invasion and baseline hepatic dysfunction.
Materials and methods: Seventeen adult liver transplantation candidates (median age 66
years, range 58–73 years; 13 men) with HCC were treated with DEB-TACE as a part of
Stage 1 of a prospective single-institution Phase II trial. All patients had marginal hepatic
reserve based on at least one of the following criteria: ascites (n=14), bilirubin between 3 and
6 mg/dL (n=5), AST 5–10 times upper normal limit (n=1), INR between 1.6 and 2.5 (n=4),
portal vein thrombosis (n=2), and/or portosystemic shunt (n=2). Primary study objectives
were safety and best observed radiographic response.
Results: Thirty-seven DEB-TACE procedures were performed. Objective response rate and
disease control rate were 63% and 88%, respectively. HCC progression was observed in 12
patients. Median time to progression was 5.6 months (range 0.9–13.6 months). Within 1
month following DEB-TACE, 13 patients (76%) developed grade 3 or 4 AE attributable to
the procedure. Four patients (all within Milan Criteria) were transplanted (2.7–6.9 months
after DEB-TACE), and 12 patients died (1.8–32 months after DEB-TACE). All deaths were
due to liver failure that was either unrelated to HCC (n=5), in the setting of metastatic HCC
(n=5), or in the setting of locally advanced HCC (n=2). Mortality rate at 1 month was 0%.
Conclusions: DEB-TACE achieves tumor responses but carries a high risk of hepatotoxicity
for liver transplant candidates with HCC and marginal hepatic reserve.
Keywords: hepatocellular carcinoma, chemoembolization, liver transplantation
Introduction
Transarterial chemoembolization (TACE) has been shown to extend survival of
patients with intermediate stage unresectable hepatocellular carcinoma (HCC)
compared with supportive care,1,2 and in optimal cases may be effective in allowing
“bridging” to liver transplantation (LT)3 or “downstaging”4–6 of the tumor to allow
transplantation. Moreover, use of TACE in the pre-transplant period has been found
to diminish drop-out from the liver transplant wait list.4–6
TACE can be performed by administering chemotherapeutic agents as an emul-
sion with ethiodized oil (conventional method, cTACE) or by delivering micro-
spheres pre-loaded with doxorubicin (drug-eluting bead TACE, DEB-TACE). Our
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group has demonstrated that pre-cTACE bilirubin ≥2 mg/
dL, aspartate or alanine aminotransferase (AST or ALT)
>5 times upper normal limit, international normalized ratio
(INR) for prothrombin time >1.5, clinical evidence of
ascites, or portal venous thrombus or flow diversion were
associated with an increased risk of severe hepatotoxicity
after cTACE.7 Multiple recent studies8–10 as well as a
meta-analysis11 have demonstrated similar efficacy of
cTACE and DEB-TACE for patients with unresectable
intermediate-stage HCC. One prospective randomized
study8 showed that the overall frequency of treatment-
related severe adverse events (AE) per 100 treatments
was lower in DEB compared to cTACE group.
Furthermore, the number of radiographic objective
responses observed for patients with Child-Pugh B and
ECOG performance status 1 were significantly higher in
DEB group.8 On the basis of this observation, DEB-TACE
may be the preferred modality for treating patients with
hepatic dysfunction.
Studies that have evaluated safety of DEB-TACE to date
have excluded patients with serum bilirubin ≥3 mg/dL, AST
or ALT levels greater than 5 times upper normal limit, or
clinically apparent ascites,8–10,12–14 owing to risk of con-
founding by the competing comorbid events of liver dysfunc-
tion, which are prevalent in this population. However,
patients with significant baseline liver dysfunction are often
referred for TACE, particularly under the paradigm of “brid-
ging” or “downstaging” to liver transplantation.5,7,15 The
purpose of this study was to evaluate safety and efficacy of
DEB-TACE for liver transplantation candidates with HCC
and significant baseline hepatic dysfunction.
Materials and methods
Study population
This single-center prospective study was approved by the
Institutional Review Board of University of California San
Francisco (IRB record #14-13092) and was deemed to be
compliant with the Declaration of Helsinki. All patients
provided written informed consent. The trial was registered
on clinicaltrials.gov (NCT# 02147301). All of the eligible
patients were referred for chemoembolization at the treat-
ment center. Incentives for study participation were not pro-
vided. The study was designed as a single-arm open-label
Phase II two-stage trial, which aimed to enroll 51 adult liver
transplant candidates with marginal hepatic reserve and liver-
limited HCC without vascular invasion or extracapsular
extension diagnosed by imaging criteria in accordance with
the Organ Procurement and Transplantation Network
(OPTN) guideline.16 The goal of first stage was to enroll 17
patients. Enrollment of the additional 34 patients was subject
to documentation of adequate safety and efficacy of DEB-
TACE during the first stage. The study was terminated after
stage 1 by the study team due to the high rates of severe
adverse events (SAE).
Eligibility required imaging16 or histologic diagnosis of
HCC with at least one previously untreated HCC tumor
nodule (measurable according to modified Response
Evaluation Criteria in Solid Tumors, mRECIST) in a pre-
viously untreated liver segment. Presence of macrovascular
tumor invasion, extracapsular extension, or extrahepatic
metastases was not allowed. Patients were required to have
impaired hepatic reserve based on the selection criteria deli-
neated by Garwood et al7 and subsequently used by
Hansmann J et al.15 Presence of at least one of the following
clinical and laboratory abnormalities was required for inclu-
sion: (A) clinical evidence of ascites, (B) serum bilirubin
between 3 and 6 mg/dL, (C) aspartate and/or alanine amino-
transferase (AST and/or ALT) level between 5 and 10 times
upper normal limit, (D) international normalized ratio for
prothrombin time (INR) between 1.6 and 2.5 in the absence
of ongoing anticoagulation therapy, (E) main portal vein
thrombosis, and (F) functioning transjugular intrahepatic
portosystemic shunt (TIPS) or surgical shunt. Patients with
impaired functional status (Eastern Cooperative Group
Performance Status, ECOG, worse than 2), impaired renal
function (serum creatinine >1.5 mg/dL), macrovascular
tumor invasion or extrahepatic disease, medically refractory
hepatic encephalopathy, symptomatic heart disease, previous
bile duct sphincterotomy or biliary-enteric anastomosis, and
liver transplant recipients were excluded.
DEB-TACE technique
DEB-TACE was performed at a single tertiary transplant
center after patients provided written informed consent for
the procedure and for study participation. All procedures
were performed by fellowship-trained interventional radi-
ologists with 5–25 years of experience with hepatic angio-
graphy and embolization. An angiographic survey of the
celiac and superior mesenteric arteries was performed via
trans-femoral approach using a 5-French catheter. Digital
subtraction angiography was also performed after selective
catheterization of the proper, right and/or left, hepatic
arteries. Cone-beam CT (Philips, Amsterdam, The
Netherlands) was used routinely. Subsegmental hepatic
artery branches were selected with a coaxially placed
Fidelman et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Journal of Hepatocellular Carcinoma 2019:694
microcatheter (Renegade 2.7-French or 2.1-French, Boston
Scientific, Natick, MA).
DEB-TACE was performed with up to two 2-mL vials of
spherical polyvinyl alcohol microspheres (LC Bead®; BTG
PLC, London, UK) impregnated per standard manufacturer-
supplied protocol with a total of 100 mg of reconstituted
doxorubicin hydrochloride powder (25 mg per milliliter of
beads; Mylan, Canonsburg, PA). Investigational Device
Exemption (IDE number G13-0023) was obtained from the
United States Food and Drug Administration (FDA) per the
requirement of the IRB. Microspheres in the size range of
100–300 microns were used. Prior to administration, each 2-
mL vial of drug-eluting beads was resuspended in 10 mL of
Omnipaque 350 contrast (Amersham Health, Princeton NJ).
Procedures were stopped when arterial flow approached sta-
sis and/or when the entire DEB dose had been administered.
If stasis had not been achieved after administration of two
vials of DEB, additional embolic was not administered.
Patients with multiple liver lesions, lesions >3 cm, or lesions
with more than one feeding hepatic artery branch received up
to 3 additional DEB-TACE at approximately 1-month inter-
vals. Additional DEB-TACE was allowed until liver trans-
plantation or untreatable progression upon demonstration of
residual and/or recurrent liver-limited HCC as long as
patients continued to meet study inclusion and had lesions
that were amenable to treatment with DEB-TACE.
Safety assessments
Adverse events (AE) were graded according to National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) version 4.03. Clinical and
laboratory evaluations were performed approximately 1, 7,
and 30 days after each DEB-TACE procedure, and
subsequently every 3 months for up to 1 year after last
DEB-TACE procedure. Laboratory investigations included
complete blood count, serum electrolytes, creatinine, liver
function tests, and prothrombin time. All AE that resulted in
at least one category increase under the CTCAE v. 4.03
definitions were followed until resolution or until completion
of follow-up. Cardiac function assessment monitoring using
transthoracic echocardiogram was performed prior to first
DEB-TACE and approximately 1 month following the last
planned (1st, 2nd, 3rd, or 4th) DEB-TACE procedure.
Efficacy assessments
Efficacy was assessed based on multi-phase dynamic con-
trast-enhanced CT or MRI (CECT or CEMRI) according to
modified Response Evaluation Criteria in Solid Tumors
(mRECIST). The same imaging modality was used for
pre- and post-treatment evaluations. Imaging was per-
formed one month following last planned DEB-TACE
procedure. Subsequently, CECT or CEMRI exams were
repeated at three-month intervals until HCC recurrence,
liver transplantation, or death. Serum alpha-fetoprotein
(AFP) levels were checked at the time of the imaging tests.
Study objectives
Primary study objectives were to determine the safety of
DEB-TACE in accordance to NCI CTCAE and to deter-
mine the best observed overall radiographic response
(ORR) rate to DEB-TACE according to mRECIST.
Secondary objectives were to determine the proportion of
patients who remained active on the wait list for a liver trans-
plant and were eventually transplanted; to determine the pro-
portion of patients who were inactivated or dropped out from
the wait list for any reason but transplantation; to measure
ORR according to mRECIST 6 months after the first planned
DEB-TACE procedure; time to progression (TTP); time to
hepatic progression (TTHP); time to progression beyond
MilanCriteria; time to untreatable progression (TTUP); overall
progression-free survival (PFS); hepatic progression-free sur-
vival (HPFS) rates at 1, 3, 6, 12, and 24 months; overall
survival (OS); to determine whether cardiac function changes
occurred as a result of DEB-TACE; and to obtain pharmaco-
kinetic data for doxorubicin administered as a part of DEB-
TACE procedures. The date of the first on-study DEB-TACE
procedure was used as the starting point for calculations of
TTP, TTHP, TTUP, PFS, HPFS, and OS. The study protocol as
well as deidentified participant data regarding TTP, TTHP,
TTUP, PFS, HPFS, and OS will be available at https://radiol
ogy.ucsf.edu/patient-care/sections/ir/ for a period for 3 years.
Pharmacokinetics
Pharmacokinetics (PK) data for doxorubicin were col-
lected per the request of the USA FDA since PK data for
100–300 micron drug-eluting microspheres has not been
previously reported. Peripheral venous blood samples
were obtained from all patients during the first planned
DEB-TACE procedure prior to chemotherapy administra-
tion, at the time of completion of DEB administration, and
subsequently 5±1 mins, 30±5 mins, 60±5 mins, 120±10
mins, 6±0.5 hrs, 20±2 hrs, and 8±2 days following DEB
administration. The data were used to determine maximum
doxorubicin concentration (Cmax) and total systemic dox-
orubicin dose (area under the curve, AUC).
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Statistical analysis
For sample size calculations, the best observed ORR was
assumed to be at least 40% in treated lesions using
mRECIST criteria. The best observed ORR of less than
20% was considered unacceptable for the study treatment.
Under binomial approximation with 5% type I error and
85% power, a total of 51 patients were required for the
study. For the purpose of safety analysis, the study was
divided into two stages. After 17 patients have received at
least 1 DEB-TACE and had potential for at least 4 weeks
of follow-up, the safety profile was analyzed. Because of
the high incidence of severe AE (SAE), the study was
terminated after completion of the first stage. The study
DEB-TACE procedures were performed between 01/12/
2015 and 06/24/2016. Data were censored on February 1,
2019. The correlation between maximum doxorubicin con-
centration (Cmax), AUC, and delivered doxorubicin dose,
serum bilirubin level, MELD-Na, and CPT, and ALBI
scores were evaluated using linear regression analysis
(SAS version 9.4, SAS Institute Inc., Cary NC).
Results
Patient population
A total of 155 adult patients with liver-limited HCC without
vascular invasion or extracapsular tumor extension who
were referred for TACE were screened for study participa-
tion between 11/01/2014 and 08/01/2015 (Figure 1). The
majority of patients (n=124) were not deemed to be study
candidates due to absence of significant underlying liver
disease (n=117), and/or poor candidacy for liver transplan-
tation (n=48), and/or lack of previously untreated liver
lesions (n=14). An additional four patients were excluded
due to impaired renal function. Of the remaining 27 patients
who met inclusion criteria and who were approached for
study participation, 4 declined to participate, 5 did not
undergo DEB-TACE due to clinical liver function decom-
pensation between screening and the scheduled procedure
date, while 1 patient underwent diagnostic angiography,
which did not reveal any targetable liver lesions. The latter
six patients were enrolled in the study and were replaced, as
allowed per protocol.
Clinical characteristics of the 17 patients treated on
study are summarized in Table 1. A total of 17 patients
(median age 66 years, range 58–73 years; 13 men) were
treated with at least 1 DEB-TACE procedure during the
first stage of the study. Hepatitis C virus infection was the
most common cause for cirrhosis (8 patients, 47%). The
majority of the patients qualified for inclusion based on
presence of symptomatic ascites (14 patients, 82%), serum
bilirubin between 3 and 6 mg/dL (5 patients, 29%), and/or
coagulopathy (4 patients, 24%). Three patients qualified
for inclusion based on presence of main portal vein throm-
bosis, patent transjugular intrahepatic portosystemic shunt
(TIPS), or a patent surgical shunt. Median CTP score was
10 (range 6–12), and median MELD score was 12 (range
Scheduled for TACE
N=155
Eligible
N=27
Good liver reserve (n=117) and/or
Not liver transplant candidate (n=48)
No previously untreated lesions (n=14) and/or
At least one of the above
N=124
Renal insufficiency
N=4
Refused consent
N=4
TACE canceled due to liver decompensation
N=5
No lesions detected on angiography (TACE aborted)
N=1
Enrolled
N=17
Figure 1 Flow diagram that demonstrates criteria for patient inclusion and exclusion.
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7–26). Most study participants (12 patients, 71%) had
HCC within Milan Criteria at the time of inclusion.
Median lesion size was 3 cm (range 1.1–6.5 cm).
Solitary lesions were present for 14 patients, while 2
patients had 2 lesions each, and 1 patient had 4 lesions.
Prior to inclusion in the study, seven patients (41%) had
received between one and seven (median 3) liver-directed
therapy procedures, which included conventional or DEB-
TACE (5 and 7 patients, respectively) or radiofrequency
ablation (3 patients).
Procedure details
A total of 37 DEB-TACE procedures were performed for
the 17 enrolled patients. Nine patients (53%) were treated
once, three patients twice, one patient three times, three
patients four times, and one patient seven times. Median
time interval between DEB-TACE was 2 months (range 1–
7 months). Median doxorubicin dose administered during
each procedure was 49 mg (range 4.9–98 mg). No major
protocol deviations were encountered.
Safety assessments
All patients experienced at least one AE as a result of the
DEB-TACE procedures (Table 2). Most common clinical
AEs were self-limited grade 1 or 2 fatigue, anorexia,
nausea, abdominal pain, and insomnia, all of which
resolved within 1 month of DEB-TACE. New Grade 3 or
4 AE attributed to DEB-TACE occurred in 13 patients
(76%). Seven patients (41%) developed symptoms of
fluid retention. Three patients (18%) had worsening
ascites, two of whom started requiring periodic large-
volume paracenteses, while one was successfully treated
with diuretics. New or worsening lower extremity edema
developed in six patients (35%) within one month of DEB-
TACE. Symptoms were grade 1 or 2 in severity for four
patients and resolved after supportive treatment and/or
diuretics within one month of onset. Two patients
Table 1 Population demographics and baseline characteristics
Demographics
Male 13 (76%)
Female 4 (24%)
Median age (range), years 66 (58 – 73)
Asian 2 (12%)
Caucasian 10 (59%)
Hispanic 4 (24%)
Other 1 (6%)
Liver disease etiologies
Alcohol 3 (18%)
HCV 3 (18%)
HCV and alcohol 5 (29%)
Non-alcoholic fatty liver disease 3 (18%)
HBV 1 (6%)
Primary sclerosing cholangitis 1 (6%)
Cryptogenic 1 (6%)
Baseline liver function
Median MELD-Na score (range) 12 (7 – 26)
Median CPT score (range) 10 (6 – 12)
Child Pugh class A / B / C 1 / 7 / 9
ALBI score grade 1 / 2 / 3 1 / 8 / 8
Liver Dysfunction Categories for
Inclusion
Symptomatic ascites 14 (82%)
Serum bilirubin 3-6 mg/dl 5 (29%)
AST > 5 times upper normal limit 1 (6%)
INR 1.6-2.5 [not on anticoagulation] 4 (24%)
Main portal vein thrombosis 1 (6%)
Patent TIPS 1 (6%)
Patent surgical splenorenal shunt 1 (6%)
ECOG performance status
0 / 1 / 2 7 (41%) / 9 (53%) / 1 (6%)
Tumor Burden
Median lesion size (range), cm 3.0 (1.1 – 6.5)
Number of lesions per patient: 1 / 2 /
3 / 4
14 / 2 / 0 / 1
Within Milan 12 (70%)
Outside Milan, but within UCSF
Downstaging
3 (18%)
Outside UCSF Downstaging 2 (12%)
BCLC stage A / B / C / D 0 / 5 (29%) / 3 (18%) / 9
(53%)
Prior therapy (patients)
No prior interventions 10 (59%)
cTACE 5 (29%)
DEB-TACE 7 (41%)
RFA 3 (18%)
AFP median (range), ng/ml 22 (6-1191)
< 20 8 (47%)
(Continued)
Table 1 (Continued).
20 – 200 4 (24%)
> 200 5 (29%)
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; MELD-Na, model
for end-stage liver disease with sodium; CPT, Child-Pugh-Turcotte; AST, aspartate
aminotransferase; INR, international normalized ratio for prothrombin time; TIPS,
transjugular intrahepatic portosystemic shunt; ECOG, Eastern Cooperative
Oncology Group; UNOS, United Network for Organ Sharing; BCLC, Barcelona
Clinic Liver Cancer; cTACE, conventional transarterial chemoembolization; DEB-
TACE, drug eluting bead transarterial chemoembolization; RFA, radiofrequency
ablation; AFP, alpha fetoprotein.
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developed severe (grade 3) leg edema, which was life-long
and refractory to diuretics. A decline in ECOG perfor-
mance status within 1 month of DEB-TACE was experi-
enced by 8 patients (47%), of whom 2 were able to regain
pre-treatment level of function within 3 months. The
remaining six patients experienced irreversible decline in
performance status.
A total of 16 patients (94%) experienced new or worsen-
ing laboratory AE within 1 month of DEB-TACE. Trends of
mean AST, ALT, and bilirubin levels following the last DEB-
TACE are shown in Figure 2. Twelve patients (71%) devel-
oped new-onset grade 3 laboratory AE, which included
hyponatremia (n=5), hyperbilirubinemia (n=3), AST
elevation (n=3), thrombocytopenia (n=3), anemia (n=2),
and creatinine elevation (n=1). All grade 3 AE returned to
baseline (majority within 30 days of DEB-TACE), except for
1 patient with hyperbilirubinemia that was attributed to an
unplanned total hip arthroplasty performed 10 days follow-
ing DEB-TACE and 1 patient with thrombocytopenia as well
as grade 4 hyponatremia.
Hepatic failure grade 3 (defined in NCI CTCAE v 4.03 as
asterixis, mild encephalopathy, and limited ability to perform
activities of daily living) was observed for 4 patients and was
deemed unrelated to DEB-TACE for 2 patients (1 patient
with previously prescribed diuretic medication non-compli-
ance and 1 patient who underwent an unplanned total hip
arthroplasty 10 days following DEB-TACE). Grade 3 hepatic
failure resolved with supportive measures for three of the
patients less than 1 month after the preceding DEB-TACE
procedure. The fourth patient was found to have metastatic
HCC to the brain and died 3 months after DEB-TACE. One
patient died from liver failure 1.8 months following the first
DEB-TACE, which may have been related to DEB-TACE.
Procedure-related mortality was 1 out of 17 (6%).
Echocardiograms demonstrated no significant change in
myocardial function.Median left ventricular ejection fraction
was 70% at baseline (range 66–81%) and 68% at 1 month
following last pre-planned DEB-TACE (range 60–74%).
Efficacy
There were 16 patients who were evaluable for radio-
graphic response. One patient did not have follow-up
cross-sectional imaging of the abdomen due to inter-cur-
rent illness unrelated to TACE.
Efficacy data are summarized in Table 3. Best observed
radiographic tumor responses according to mRECISTwere
complete, partial, and stable disease response rates of
25%, 38%, and 25%, respectively. Best observed ORR
and disease control rate (DCR) were 63% and 88%,
respectively. Median time from the first DEB-TACE to
best observed ORR was 1.2 months (range 0.9–9.6
months). ORR and DCR at 6 months were 38% and
46%, respectively. Median number of DEB-TACE proce-
dures required to achieve maximum observed response
was 1 (range 1–7). HCC progression was observed in 12
patients. Median time to progression was 5.6 months
(range 0.9–13.6 months). HCC progression to beyond
Milan Criteria was observed for 8 patients (5 patients
with extrahepatic metastases, 2 with multifocal HCC out-
side Milan Criteria, and 1 with portal vein tumor throm-
bus) after a median time of 5.6 months (range 1.4–30.4
Table 2 All-cause adverse events observed within 30 days of
DEB-TACE procedure
AE Category Baseline
Grade 1 / 2 / 3 / 4
Post-
Treatment
Grade 1 / 2 /
3 / 4
Clinical
Anorexia 0 / 0 / 0 / 0 5 / 1 / 0 / 0
Ascites 7 / 3 / 4 / - 5 / 3 / 5 / -
Constipation 0 / 0 / 0 / 0 1 / 0 / 0 / 0
Diarrhea 0 / 0 / 0 / 0 2 / 0 / 0 / 0
Dyspnea 2 / 0 / 0 / 0 2 / 0 / 0 / 0
Edema of limbs 4 / 0 / 0 / 0 5 / 1 / 2 / 0
Fatigue 2 / 1 / 0 / 0 7 / 3 / 0 / 0
Fever 0 / 0 / 0 / 0 2 / 0 / 0 / 0
Hepatic failure 0 / 0 / 0 / 0 0 / 0 / 4 / 0
Hiccups 0 / 0 / 0 / 0 0 / 1 / 0 / 0
Insomnia 0 / 1 / 0 / 0 2 / 2 / 0 / 0
Nausea 0 / 0 / 0 / 0 5 / 2 / 0 / 0
Pain 0 / 0 / 0 / 0 4 / 2 / 2 / 0
Vomiting 0 / 0 / 0 / 0 0 / 0 / 0 / 0
Laboratory
Hyperbilirubinemia 2 / 6 / 4 / 0 2 / 5 / 7 / 0
AST elevation 10 / 2 / 0 / 0 10 / 3 / 3 / 0
ALT elevation 2 / 0 / 0 / 0 7 / 1 / 0 / 0
Alkaline phosphatase
elevation
15 / 0 / 0 / 0 14 / 2 / 0 / 0
Hypoalbuminemia 3 / 10 / 1 / - 1 / 12 / 1 / -
Hyponatremia 8 / - / 3 / 0 7 / - / 7 / 1
Leukopenia 1 / 5 / 0 / 0 1 / 4 / 0 / 0
Hemoglobin 12 / 2 / 1 / 0 10 / 4 / 3 / 0
Thrombocytopenia 9 / 3 / 2 / 1 7 / 2 / 5 / 1
Creatinine elevation 4 / 0 / 0 / 0 7 / 0 / 1 / 0
INR elevation 11 / 1 / 0 / - 11 / 3 / 0 / -
ECOG performance
status
0 / 1 / 2 / 3
7 / 9 / 1 / 0 5 / 6 / 5 / 1
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months). Median time to untreatable progression was 9.7
months (range 1.4–30.4 months). Nine patients (53%) had
baseline AFP greater than 20 ng/mL at the time of first on-
study DEB-TACE procedure (median 214 ng/mL, range
22–1191 ng/mL). Five of these patients (56%) demon-
strated at least 50% reduction in AFP level from the
6 120
AST Mean
ALT Mean100
80
60
40
20
0
5 Bilirubin [mg/dl]
4
3
2
1
0
Baseline 1d 7d 1m 3m 6m 9m 12m Baseline 1d 7d 1m 3m 6m 9m 12m
A B
Figure 2 Trends of mean serum bilirubin (A), AST and ALT (B) levels following the last DEB-TACE procedure.
Table 3 Efficacy data
Category Result, N (%)
Best observed radiographic response (mRECIST)
Complete response
Partial response
Stable disease
Progressive disease
4 (25%)
6 (38%)
4 (25%)
2 (12%)
Time to maximum response* 1.2 (0.9–9.6) months
Objective Response Rate (ORR)
Best observed
6 months after first DEB-TACE
10 (63%)
5 (38%)
Disease Control Rate (DCR)
Best observed
6 months after first DEB-TACE
14 (88%)
6 (46%)
Time to progression (TTP)* 5.6 (0.9–13.6) months
Time to hepatic progression (TTHP)* 5.9 (0.9–13.6) months
Time to progression beyond Milan Criteria* 5.6 (1.4–30.4) months
Time to untreatable progression (TTUP)* 9.7 (1.4–30.4) months
Progression-free survival (PFS) rate at
3 months
6 months
12 months
24 months
14 (82%)
10 (59%)
6 (35%)
4 (24%)
Hepatic progression-free survival (HPFS)* 6.5 (0.9–30) months
Overall survival (OS)* 11.4 (1.8–32) months
Alpha-fetoprotein responders (n=5)*
Prior to first on-study DEB-TACE (baseline)
At time of best observed radiographic response (nadir)
248 (22–384) ng/mL
16 (2.2–56.4) ng/mL
Notes: *Median (range).
Dovepress Fidelman et al
Journal of Hepatocellular Carcinoma 2019:6 submit your manuscript | www.dovepress.com
DovePress
99
median of 248 ng/mL to median of 16 ng/mL at the time
of best observed radiographic response.
Clinical follow-up
Of the 17 patients treated, 4 patients (24%) received ortho-
topic liver transplants a median of 3.1 months (range 2.7–6.9
months) after the first DEB-TACE. These patients had HCC
within Milan Criteria at the time of the first DEB-TACE. All
of the patients who had received a liver transplant were alive
at the time of the study censor date of 02/01/2019 and were
without HCC recurrences following a median 44.1 months
(range 39.7–45.9 months) of follow-up.
After discontinuation of DEB-TACE, additional anti-can-
cer therapy was administered to nine patients (53%), one of
whom ultimately received a liver transplant. These patients
received a median of 2 (range 1–5) courses of treatment a
median of 2.7 months (range 1.2–4.8 months) following the
last DEB-TACE procedure. Modalities included stereotactic
body radiotherapy (4 patients), percutaneous ethanol injec-
tion (3 patients), conventional TACEwith doxorubicin, mito-
mycin C, ethiodized oil, and gelatin sponge slurry (2
patients), and sorafenib (1 patient). Conventional TACE
was used following discontinuation of DEB-TACE in
selected patients due to partial obliteration of the arterial
supply, which resulted from previous hepatic artery emboli-
zation. It was expected that a liquid embolic (emulsion of
chemotherapy and ethiodized oil) would pass through the
small caliber collateral vessels supplying liver tumors more
readily than microspheres.
A total of 13 patients were removed from the transplant
list due to detection of extrahepatic HCC metastases (5
patients), locally advanced untreatable HCC (2 patients),
frailty (4 patients), severe coronary artery disease (1 patient),
and lack of interest in transplantation (1 patient). Twelve
patients died 1.8–32 months after the first on-study DEB-
TACE (median overall survival 11.4 months). Mortality rates
at 1, 3, 6, 9, and 12 months were 0%, 12%, 18%, 24%, and
29%, respectively. All deaths were due to hepatic failure that
was either unrelated to HCC (n=5), in the setting of meta-
static HCC (n=5), or in the setting of locally advanced HCC
(n=2). One patient was not transplanted and was lost to
follow-up 21 months following first DEB-TACE.
Pharmacokinetic profile
The pharmacokinetic analysis for doxorubicin demon-
strated that peak drug concentration (Cmax) was reached
within 5 mins after drug-eluting microsphere administra-
tion (Figure 3). Mean and median Cmax were 71.2 and 42.2
ng/mL. Cmax range was 8.4–444.4 ng/mL. Standard devia-
tion was 103.1 ng/mL. Cmax values for 15 of the patients
were less than 100 ng/mL. Mean and median AUC were
592 and 593 ng/mL-hr. AUC range was 175–2030 ng/mL-
hr. Standard deviation was 310 ng/mL-hr. No significant
correlation between either Cmax or AUC and delivered
doxorubicin dose, serum bilirubin level, MELD-Na, and
CPT, and ALBI scores could be demonstrated.
Discussion
This study provided prospectively acquired data on the
outcomes of DEB-TACE for patients with HCC and mar-
ginal hepatic reserve. In current clinical practice, bridging
and downstaging liver-directed therapy is offered to
patients with HCC who have varying levels of liver func-
tion impairment. Of 606 patients with HCC who under-
went liver-directed therapy for bridging or downstaging to
liver transplantation5 at a US transplant center with long
expected waiting time on the transplant list, 232 patients
(38%) had Child-Pugh class B cirrhosis, while 67 patients
(11%) had Child-Pugh class C cirrhosis at the time of
listing.
The majority of the published studies on TACE have
focused on patients with preserved liver function (CPT
score 5–7), no clinical evidence of ascites, and patent
portal vein.8–10,12–14 Limited data on the value of TACE
for patients with hepatic dysfunction and decompensation
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are available. A retrospective study based on a population
of 1,344 patients with HCC and Child-Pugh C cirrhosis
demonstrated that TACE was associated with a significant
survival prolongation (10 months versus 7 months)
compared to best supportive care.17 Similarly, another
retrospective multi-center study of 236 patients with
Child-Pugh C cirrhosis and HCC was able to demonstrate
an improvement in overall survival from 13.8 to 22.2
months for patients who received liver-directed therapy,
either TACE or thermal ablation.18
In this study, the majority of patients (76%) developed
severe (Grade 3 or 4) AE attributed to DEB-TACE, which
included four patients with clinical hepatic failure. Therewas 1
death that occurred 1.8 months following DEB-TACE in the
setting of decompensated hepatic failure that may have been in
part due to the procedure. The rate of severe treatment-related
AE was higher than previously reported in other studies
describing high-risk patients.7,19 For instance, a large retro-
spective study by Garwood et al7 has reported on 251 patients
with hyperbilirubinemia, coagulopathy and/or clinically evi-
dent ascites who underwent 443 conventional TACE proce-
dures. Grade 3 or 4 hepatotoxicity developed after 90 TACE
procedures (20%) in 78 patients (31%). Liver function
abnormalities became irreversible after 41 procedures (9%)
in 37 patients. Six patients (2%) received urgent liver trans-
plants, and 5 (2%) patients died within 30 days of TACE in the
setting of irreversible severe hepatotoxicity. Another study by
Kothary et al19 reported complications outcomes for 52
patients with hyperbilirubinemia, hypoalbuminemia, CTP
score >9, multifocal HCC, a TIPS, and/or biliary obstruction
who underwent 65 TACE procedures. The procedure-related
morbidity rate was 10.8%, and the 30-day mortality rate was
7.7%. Similar to the study By Garwood et al,7 the majority of
adverse events observed in this clinical trial were self-limited.
The higher rate of AE reported in this study is likely
related to the differences in the patient populations and to
more complete AE reporting in a prospective trial. Patients
included in this study were at risk for developing liver
decompensation even without liver-directed therapy, as
evidenced by the observation that five patients were not
able to undergo DEB-TACE after enrollment (Figure 1).
DEB-TACE proved to be an effective means of local
tumor control, with reported best observed ORR and DCR
of 63% and 88%, respectively. ORR and DCR at 6 months
were 38% and 46%, respectively. Lammer et al8 reported
somewhat higher ORR and DCR at 6 months (51.6% and
63.4%) in a cohort of patients with significantly better
liver function.
DEB-TACE was an effective bridging strategy for four
of 12 patients (33%) with HCC within Milan Criteria who
ultimately received liver transplants. The other eight
patients dropped out from the transplant list due to a
variety of causes including development of extrahepatic
metastases, locally advanced untreatable HCC, and frailty.
All five patients with HCC tumor burden outside Milan
Criteria dropped out from the transplant list due to a
similar set of causes. The 33% rate of survival to trans-
plantation observed in this study for patients within Milan
is considerably lower than the 68% rate reported for a
large population of patients with HCC with predominantly
Child-Pugh A cirrhosis who were within Milan Criteria at
the time of listing.5 This finding suggests that poor liver
function may be an independent factor for drop-out from
liver transplant list. The observed lack of patients outside
Milan who survived until transplantation suggests that
DEB-TACE may not be a suitable downstaging strategy
for patients who present with significant hepatic dysfunc-
tion, especially at transplant centers with long expected
waiting times.
The pharmacokinetic profile of doxorubicin release
from drug-eluting microspheres has been studied for
microspheres in 500–700 micron size.13 However, PK
data for doxorubicin release from smaller microspheres
have not been previously published. Our study demon-
strated that the pharmacokinetic pattern of doxorubicin
release from 100 to 300 micron microspheres mirrors the
pattern observed by Varela et al13 for 500–700 micron
particles. Maximum doxorubicin concentration in plasma
(Cmax) occurred at 5 mins following completion of parti-
cle deposition, and the observed AUC range of 175–2030
ng/mL-hr was similar to the values observed by Varela et
al and was independent of the delivered doxorubicin dose.
This study is limited by small sample size and heterogene-
ity of the high-risk population. Patients with a number of high-
risk factors were allowed for participation, including ascites,
hyperbilirubinemia, transaminitis, coagulopathy, main portal
vein thrombosis, and a portosystemic shunt. Seven of the
patients have had liver-directed therapy (including TACE)
prior to study enrollment, which could have an effect on the
underlying liver function. It is possible that previous liver-
directed therapy has contributed to the underlying liver dys-
function at the time of study enrollment. Patients with liver
dysfunction that develops in the course of HCC therapy are
routinely encountered at transplant centers with long waiting
times. Thus, the cross-section of patients included in this study
depicts a representative population of liver transplant
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candidates with HCC and liver dysfunction who may undergo
TACE for bridging to transplantation. It is unlikely that prior
trans-arterial therapy had an effect on technical ability to per-
form on-study DEB-TACE, as patients were required to have
previously untreated lesions in liver segment(s) that have not
been previously targeted for embolization.
The investigators elected to terminate the study after com-
pletion of Stage I due to one death that was possibly related to
study treatment. This study lacked a control arm. Conventional
TACE or transarterial embolization control arm would be
reasonable to include in a future study multi-center study,
which could focus on transplant candidates with HCC within
Milan Criteria and CPTscore 9–12 with the goal of increasing
the odds of survival to liver transplantation and limiting parti-
cipation to patients with marginal liver reserve.
In conclusion, this small prospective study suggests
that DEB-TACE achieves tumor responses but carries a
high risk of severe toxicity and, therefore, may not be a
safe bridging or down-staging strategy for liver transplant
candidates with HCC and marginal liver reserve.
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